ENLV Enlivex Therapeutics Ltd. Stock Quote

ENLV [NASD]

Index	-	P/E	-	EPS (ttm)	-0.86	Insider Own	24.65%	Shs Outstand	14.37M	Perf Week	-15.27%
Market Cap	175.46M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	9.83M	Perf Month	-17.15%
Income	-11.80M	PEG	-	EPS next Q	-0.21	Inst Own	10.70%	Short Float	0.68%	Perf Quarter	-57.97%
Sales	-	P/S	-	EPS this Y	19.00%	Inst Trans	3.04%	Short Ratio	0.27	Perf Half Y	-17.64%
Book/sh	2.47	P/B	3.93	EPS next Y	-	ROA	-32.20%	Target Price	-	Perf Year	85.31%
Cash/sh	1.98	P/C	4.91	EPS next 5Y	-	ROE	-37.50%	52W Range	4.49 - 29.40	Perf YTD	15.18%
Dividend	-	P/FCF	-	EPS past 5Y	53.90%	ROI	-	52W High	-66.97%	Beta	1.08
Dividend %	-	Quick Ratio	8.70	Sales past 5Y	-	Gross Margin	-	52W Low	116.26%	ATR	0.78
Employees	50	Current Ratio	8.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	38.87	Volatility	7.57% 7.31%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-37.20%	Profit Margin	-	Rel Volume	0.17	Prev Close	10.04
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	246.99K	Price	9.71
Recom	-	SMA20	-9.18%	SMA50	-17.99%	SMA200	-5.80%	Volume	69,419	Change	-3.29%

Mar-02-21

Reiterated

H.C. Wainwright

Buy

$22 → $33

Mar-22-21 08:00AM	Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra in Combination with Immune Checkpoint Inhibitors GlobeNewswire
Mar-09-21 08:00AM	Enlivex Announces Upcoming Virtual Investor Conference Participations GlobeNewswire
Mar-08-21 08:00AM	Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies GlobeNewswire
Mar-01-21 07:55AM	Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors GlobeNewswire
Feb-22-21 08:00AM	Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy GlobeNewswire -10.11%
Feb-18-21 08:00AM	Enlivex Announces Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire -8.17%
Feb-16-21 08:30AM	Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohns Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy GlobeNewswire
Feb-12-21 05:21PM	Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares GlobeNewswire -5.17%
Feb-09-21 11:25PM	Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares GlobeNewswire
05:25PM	Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares GlobeNewswire
Feb-03-21 12:34PM	Enlivex Rallies On Encouraging Allocetra Data In Mid-Stage COVID-19 Study Benzinga +6.97%
07:55AM	Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update GlobeNewswire
Jan-11-21 08:00AM	Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire +6.33%
Dec-31-20 12:46AM	Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth Simply Wall St. -8.57%
Dec-21-20 08:00AM	Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv GlobeNewswire
Dec-09-20 01:10PM	Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News Zacks -6.31%
Dec-07-20 08:00AM	Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy GlobeNewswire -11.31%
Dec-03-20 01:09PM	Why Sutro, Lumos And More Health Care Stocks Are Moving Today Benzinga +37.85%
08:00AM	Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients GlobeNewswire
Nov-18-20 08:00AM	Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra GlobeNewswire +6.98%
Nov-17-20 08:18AM	Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Companys Board of Directors GlobeNewswire
Nov-11-20 08:14AM	Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwrights 6th Annual Israel Conference GlobeNewswire
Nov-05-20 08:30AM	Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohns Disease, and Ulcerative Colitis with Allocetra Immunotherapy GlobeNewswire
Nov-03-20 01:44PM	What's in the Cards for Enlivex (ENLV) This Earnings Season? Zacks +5.34%
09:12AM	Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients GlobeNewswire
Oct-27-20 08:00AM	Enlivex to Host COVID-19 Webinar: The Staging of a New Disease and Its Implications for Treatment Options, with Mount Sinai Key Opinion Leader GlobeNewswire
Oct-22-20 08:45AM	Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients GlobeNewswire
Oct-13-20 09:28AM	Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients GlobeNewswire +22.74%
Oct-02-20 09:16AM	What You Need To Know About Enlivex Therapeutics Ltd.'s (NASDAQ:ENLV) Investor Composition Simply Wall St. +17.75%
Oct-01-20 04:31PM	Bed Bath & Beyond, Enlivex: 5 Top Stock Gainers for Thursday TheStreet.com +47.98%
09:40AM	Enlivex Pharmaceutical Shares Surge After Positive COVID-19 Treatment Data TheStreet.com
08:18AM	The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut Benzinga
06:00AM	Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition GlobeNewswire
Sep-16-20 08:00AM	Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy GlobeNewswire
Aug-25-20 08:00AM	Enlivex Announces Allowance of New U.S. Patent Covering Allocetra Immunotherapy GlobeNewswire +6.69%
Aug-10-20 08:00AM	Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure GlobeNewswire
Jul-20-20 08:20AM	Enlivex Announces a new publication Apoptotic cell therapy for cytokine storm associated with acute severe sepsis in Cell Death & Disease, a Nature Research Journal GlobeNewswire
Jun-18-20 08:30AM	Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy GlobeNewswire
Jun-01-20 08:00AM	Enlivex Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference GlobeNewswire
May-28-20 08:30AM	Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting GlobeNewswire
May-20-20 06:56AM	We're Not Very Worried About Enlivex Therapeutics's (NASDAQ:ENLV) Cash Burn Rate Simply Wall St.
May-07-20 08:00AM	Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients GlobeNewswire
Apr-13-20 08:25AM	Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials GlobeNewswire
Mar-18-20 08:00AM	Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis GlobeNewswire -25.10%
Mar-09-20 08:13AM	Israel Patent Office Grants New Patent Covering Enlivexs Allocetra Immunotherapy Treatment GlobeNewswire
Mar-05-20 08:15AM	Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering GlobeNewswire -9.74%
Mar-03-20 08:53AM	Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea GlobeNewswire
Mar-02-20 08:00AM	Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering GlobeNewswire -21.79%
Feb-26-20 01:46PM	Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering GlobeNewswire +8.28%
Feb-25-20 03:25PM	18 Medical Stocks To Watch Amid The Coronavirus Outbreak Benzinga -10.08%
Feb-24-20 01:54PM	Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering GlobeNewswire -7.12%
08:18AM	Enlivex's stock rockets after plans to boost in capacity for treatment of COVID-19-like symptoms MarketWatch
06:30AM	Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure GlobeNewswire
Feb-20-20 08:38AM	Data On Enlivexs Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida GlobeNewswire
Nov-21-19 07:30AM	Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares GlobeNewswire -7.85%
Nov-20-19 04:14PM	Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares GlobeNewswire -5.91%
Nov-18-19 08:30AM	Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis GlobeNewswire +5.25%
Nov-12-19 07:30AM	Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference GlobeNewswire
Nov-05-19 08:42AM	Company News For Nov 5, 2019 Zacks -6.67%
Nov-04-19 07:30AM	Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis GlobeNewswire +12.34%
Oct-30-19 11:55AM	Enlivex Therapeutics (NASDAQ:ENLV) Is In A Good Position To Deliver On Growth Plans Simply Wall St.
Oct-24-19 07:30AM	Enlivex Announces Appointment of New Chief Executive Officer GlobeNewswire -5.96%
Oct-10-19 07:30AM	Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies GlobeNewswire -10.81%
Oct-08-19 07:30AM	European Patent Office Grants New Patent Covering Enlivexs Allocetra Immunotherapy Treatment GlobeNewswire -11.98%
Oct-07-19 07:30AM	Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organizations 2019 Cell Death in Immunity and Inflammation Workshop GlobeNewswire -6.47%
Sep-23-19 07:30AM	First Data On Combination Of Enlivexs Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference GlobeNewswire +7.21%
Sep-09-19 07:30AM	New Patent Covering Enlivexs AllocetraTM Immunotherapy Was Allowed By The Israeli Patent Authority GlobeNewswire
Sep-04-19 07:30AM	Enlivex Therapeutics To Present At The 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co. GlobeNewswire
Aug-19-19 07:30AM	Enlivex Therapeutics Announces Positive Outcome From Safety Committees Review Of Six Patients With Severe Sepsis Patients; Enrollment Of Last Study Cohort Approved GlobeNewswire
Aug-01-19 03:50PM	Can We See Significant Insider Ownership On The Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Share Register? Simply Wall St.
Jul-16-19 07:30AM	Immunotherapy Company Enlivex Announces Dual Listing on the Tel-Aviv Stock Exchange GlobeNewswire +9.75%
Jun-18-19 07:30AM	Australian Patent Office Grants New Patent Covering Enlivexs AllocetraTM Immunotherapy Treatment GlobeNewswire
Jun-06-19 07:30AM	Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients GlobeNewswire -8.34%
May-30-19 08:35AM	Enlivex Therapeutics to Present at The 2019 Jefferies Global Healthcare Conference GlobeNewswire
Apr-18-19 08:15AM	IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS SELECTED TO RECEIVE AN ADDITIONAL $1 MILLION GRANT BY THE ISRAEL INNOVATION AUTHORITY FOR ITS SEPSIS CLINICAL PROGRAM GlobeNewswire -5.59%
Apr-08-19 07:30AM	IMMUNOTHERAPY COMPANY ENLIVEX THERAPEUTICS COMPLETES PREVIOUSLY ANNOUNCED FINANCING PRICED AT $12.25 PER SHARE, RAISING A TOTAL OF APPROXIMATELY $8.4 MILLION GlobeNewswire
Apr-04-19 09:31AM	ENLIVEX THERAPEUTICS TO PRESENT AT THE 2019 H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE GlobeNewswire
Mar-26-19 07:30AM	Immunotherapy Company Enlivex Therapeutics Announces Nasdaq Listing Under Symbol ENLV and Closing of Private Placement of Ordinary Shares Priced at $12.25 Per Share GlobeNewswire -10.45%

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience